RecruitingACTRN12621001627842

Western Australia Asbestos Review Program

Western Australia Asbestos Review Program: medical follow up of West Australians exposed to asbestos


Sponsor

Sir Charles Gairdner Hospital

Enrollment

6,000 participants

Start Date

Feb 1, 1990

Study Type

Observational

Conditions

Summary

This is a longitudinal observational study that will monitor the health of Western Australians who have been exposed to asbestos through an annual clinical review. Who is it for? You may be eligible for this study if you are a resident of Western Australia aged 16 years or older, you are an asbestos exposed ex-worker and/or ex-resident of Wittenoom (the asbestos mine), or if you are an individual with more than 3 months cumulative asbestos exposure and/or radiological evidence of asbestos related disease. Study details All participants who choose to enrol in this study will be asked to undergo a general and lung health assessment, lung function tests and an ultra-low dose CT scan of the chest to look for lung disease from asbestos. The Western Australian Asbestos Review Program (ARP) also performs blood tests to see if we can find markers of lung disease to help diagnose problems earlier. Each of these investigations will be completed annually, the appointment usually takes about two hours. The ARP has no limit on age or how long it is since first exposure to asbestos – the study aims to follow as many people exposed to asbestos for as long as possible. It is hoped this research will provide important information that will allow clinicians to further characterise, diagnose and understand asbestos-related diseases. This information may then be used to improve health outcomes of future patients who have been affected by asbestos exposure.


Eligibility

Sex: Both males and femalesMin Age: 16 Yearss

Plain Language Summary

Simplified for easier understanding

Asbestos exposure can cause serious lung diseases — including lung cancer and mesothelioma — that may not appear for decades after exposure. The Western Australia Asbestos Review Program (ARP) is a long-term monitoring program that aims to detect these diseases early in people who were exposed to asbestos, particularly former workers and residents of Wittenoom (a former asbestos mining town in WA). Participants in this program receive an annual health check that includes lung function tests, an ultra-low dose CT scan of the chest, and blood tests looking for early markers of disease. By following participants over many years, researchers hope to better understand when and how asbestos-related diseases develop, and to identify ways to diagnose them earlier when treatment is more effective. You may be eligible if you are 16 or older, live in Western Australia, and have had at least 3 months of asbestos exposure, lived or worked at Wittenoom, or have radiological evidence of asbestos-related disease. People with unstable or untreated medical conditions who cannot attend annual appointments are not eligible.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

A two hour annual review at of persons exposed to asbestos during work or otherwise including general health and specific respiratory questionnaire, blood draw for biomarkers and DNA and lung function

A two hour annual review at of persons exposed to asbestos during work or otherwise including general health and specific respiratory questionnaire, blood draw for biomarkers and DNA and lung function followed by ultra-low dose computed tomography (CT) imaging of the chest. Anticipated duration of follow annual up is up to 30 years although participants may choose to continue after this time. Annual reviews and prospective data collection have occured since 1990. There is no retrospective data collection.


Locations(1)

Sir Charles Gairdner Hospital - Nedlands

WA, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12621001627842


Related Trials